FDA posts nationwide recall of biQ-FEL over hidden drug ingredients

A&P Creations LLC is recalling biQ-FEL nationwide after FDA testing found undeclared sildenafil and tadalafil in the 500 mL supplement. The company announced the recall on September 14, 2026, and FDA published it the next day. The product was distributed directly to U.S. consumers through Amazon, Walmart.com, and naturefuel.us, and the recall applies to two listed lots. (fda.gov)

The recall follows an earlier FDA consumer warning about biQ-FEL published in late May 2026, when the agency advised consumers not to purchase or use the product because laboratory analysis had already confirmed hidden drug ingredients. FDA’s health fraud database also lists biQ-FEL and another A&P Creations product, X10 Natural Enhancement Supplement, in connection with undeclared sildenafil and tadalafil, indicating this action did not emerge in isolation. (fda.gov)

According to the recall notice, the affected product is a liquid sold in a 500 mL bottle labeled biQ-FEL, with Spanish-language text including “Sabor artificial Hierbabuena.” The listed lots are biQ-f001-06-25 with expiration date 05/06/27 and biQ-003-01-26 with expiration date 01/01/28; one listing includes UPC 7709799120663. A&P Creations said it distributed the finished product but did not manufacture or formulate it. As of September 14, the company said it had not received any adverse event reports. (fda.gov)

FDA’s concern is straightforward: sildenafil and tadalafil are prescription drug ingredients, and they weren't declared on the label. In people, those ingredients can interact with nitrate medications such as nitroglycerin and lead to dangerously low blood pressure. FDA categorized the product within its health fraud recall listings, which is consistent with the agency’s broader scrutiny of supplements sold online that are marketed with drug-like effects while bypassing prescription oversight and labeling requirements. (fda.gov)

While public expert commentary on this specific recall appears limited so far, the regulatory context is familiar. FDA has repeatedly warned that sexual enhancement products sold online are a common source of undeclared PDE-5 inhibitors, and A&P Creations’ separate recall of X10 on the same date reinforces that this may be a company-level or supply-chain quality issue rather than a one-off labeling error. That inference is supported by FDA’s multiple postings tied to the same firm and the same hidden ingredients. (fda.gov)

Why it matters: For veterinary teams, the direct recall is aimed at human consumers, but the spillover risk is relevant in practice. Hidden pharmaceuticals in household supplements can complicate accidental pet exposures, obscure a toxicology history, and make triage harder when pet parents don't realize a product contains an active drug. This is especially important for emergency, poison-control, and general practice settings, where unexplained hypotension, lethargy, GI signs, or multi-pet household access may prompt questions about supplements or internet-purchased products in the home. The case also underscores a broader client education point: “natural” or supplement branding doesn't reliably predict safety, composition, or regulatory review. (fda.gov)

What to watch: The next signals will be whether FDA expands enforcement, whether more adverse events are reported, and whether additional products linked to A&P Creations or related distributors are added to FDA’s recall or health fraud databases in the coming weeks. (fda.gov)